FBP11/HYPA is a mammalian homologue of yeast splicing factor Prp40. The first WW domain of FBP11/HYPA (FBP11 WW1) is essential for preventing severe neurological diseases such as Huntington disease and Rett syndrome and strongly resembles the WW domain of FCA, the essential regulator for flowering time control. We have solved the structure of FBP11 WW1 and a Pro-Pro-Leu-Pro ligand complex, and demonstrated the binding mechanism with mutational analysis using surface plasmon resonance. The overall structure of FBP11 WW1 in the complex form is quite similar to the structures of WW domains from Group I and IV in complexes. In addition, conformation of FBP11 WW1 does not change much upon ligand binding. The binding orientation of the ligand against FBP11 WW1 is the same as that of the Group IV WW domainligand complex, but opposite to that of the Group I complex. The ligand interacts with two grooves formed by surface aromatic residues. The Pro and Leu residues in the ligand interact with the grooves and the Loop I region of FBP11 WW1, respectively, which are necessary interactions for binding the ligand. Interestingly, the two aromatic grooves recognize the Pro residues in entirely different manners, which allows FBP11 WW1 to recognize shorter sequences than the SH3 domain. Combined with homology models of other WW domains, the present report shows the detailed mechanism of ligand binding by Group II/III WW domains, and provides information useful in designing drugs to treat neurodegenerative diseases.
FBP11/HYPA is a mammalian homologue of yeast splicing factor Prp40. The first WW domain of FBP11/HYPA (FBP11 WW1) is essential for preventing severe neurological diseases such as Huntington disease and Rett syndrome and strongly resembles the WW domain of FCA, the essential regulator for flowering time control. We have solved the structure of FBP11 WW1 and a Pro-Pro-Leu-Pro ligand complex, and demonstrated the binding mechanism with mutational analysis using surface plasmon resonance. The overall structure of FBP11 WW1 in the complex form is quite similar to the structures of WW domains from Group I and IV in complexes. In addition, conformation of FBP11 WW1 does not change much upon ligand binding. The binding orientation of the ligand against FBP11 WW1 is the same as that of the Group IV WW domainligand complex, but opposite to that of the Group I complex. The ligand interacts with two grooves formed by surface aromatic residues. The Pro and Leu residues in the ligand interact with the grooves and the Loop I region of FBP11 WW1, respectively, which are necessary interactions for binding the ligand. Interestingly, the two aromatic grooves recognize the Pro residues in entirely different manners, which allows FBP11 WW1 to recognize shorter sequences than the SH3 domain. Combined with homology models of other WW domains, the present report shows the detailed mechanism of ligand binding by Group II/III WW domains, and provides information useful in designing drugs to treat neurodegenerative diseases.
FBP11
2 /HYPA is a mammalian homologue of yeast splicing factor Prp40 and acts to enhance the efficiency of splicing in mammalian cells (1) . WW domains of FBP11/HYPA and its related proteins bind to huntingtin, the protein responsible for Huntington disease (2, 3) . In addition, a loss of binding of these WW domains to methyl-CpG-binding protein MeCP2 leads to symptoms of Rett syndrome (4) . Thus, WW domains of FBP11 are directly involved in development of these severe neurological disorders.
FBP11/HYPA has two WW domains that bind to prolinerich ligands, including those with the -Pro-Pro-Leu-Prosequence, the PL motif (5) . The first WW domain of FBP11/ HYPA is highly similar to the FCA WW domain (FCA WW), which binds to a PL motif of FY in Arabidopsis thaliana (6) . Interaction between FCA and FY is essential to a pathway regulating the flowering transition in A. thaliana.
The WW domain is a well known protein module that mediates protein-to-protein interactions by binding to proline-containing ligands. Recent structural studies have revealed that WW domains have a -Xaa-Pro-binding groove (XP groove) that recognizes proline residues (7, 8) . The aromatic residues, Trp and Tyr, form the groove.
Originally, the PL and PR motifs were proposed as the ligands specific to Group II and III WW domains, respectively (5, 9). More recently, several studies have shown that many Group II and III WW domains have common ligand specificity, leading to the new definition of one larger group referred to as Group II/III, which was formed by merging Groups II and III (10 -12) . Based on structure model analyses, Sudol, Macias (11, 13, 14) , and we have proposed that Group II/III WW domains have a common surface patch referred to as "the second -Xaa-Probinding groove (XP2 groove)" that is composed of a few aromatic residues on the surface of Group II/III WW domains. Thus, the XP2 groove has a composition similar to the XP groove that recognizes the -Xaa-Pro-sequence in ligands of all WW domains including Groups I and IV as well as Group II/III and is expected to contribute to the recognition of Pro-rich sequences in ligands for Group II/III WW domains.
In the present report, we determined the NMR structure of the complex of FBP11 WW1 bound to a PL motif peptide to elucidate the ligand-binding mechanism of Group II/III WW domains. As expected, the XP2 groove is present on the FBP11 WW1 surface and is essential for recognition of the -Pro-Prosequence in the PL motif peptide. However, the manner in which Pro residues on the ligand are recognized by the XP2 groove differs significantly from that in which the XP groove recognizes the ligand. The mechanism of ligand recognition by the XP-XP2 groove system is fundamentally different from that of the SH3 domain. The PL motif peptide forms a PPII helix, which is seen in many other Pro-rich sequences composed of trans-proline residues, and interestingly the binding orientation of the ligand against the WW domain is opposite to that of the Group I ligands, but the same as that of Group IV ligands. We have also carried out mutant analysis with binding experiments to discuss the structure-function relationship and the differences between the structure we observed and that reported by Pires et al. (15) . Detailed information about binding of FBP11 WW1 and the PL motif is quite important because highly similar binding underlies flowering time control and the molecular pathology of severe neurological disorders such as Huntington disease and Rett syndrome.
MATERIALS AND METHODS
Sample Preparation-Detailed information regarding sample preparation of FBP11 WW1 has been reported previously (16, 17) . Briefly, cDNA of FBP11 WW1 was inserted into pGEX-4T1 (GE Healthcare). The plasmid was harbored in BL21(DE3) (Novagen) and cultivated at 37°C. To prepare 15 Nand 13 C/ 15 N-labeled FBP11 WW1, we used 15 N-and 13 C/ 15 Nlabeled C.H.L. medium (Chlorella Industry, Japan) following the manufacturer's guidelines. Purification of GST-FBP11 WW1 was carried out with glutathione-Sepharose (GE Healthcare). After the digestion of GST-FBP11 WW1 by thrombin, reverse-phase chromatography was carried out to separate GST and FBP11 WW1. The final product consisted of 30 residues, in which the first two, Gly and Ser, were from the vector pGEX-4T1.
DNA of a PL motif sequence from yeast Bbc1p was produced by annealing synthesized DNAs and inserting them into pGEX-4T1. Expression and purification of the GST-PL motif peptide was carried out by the same method as that for FBP11 WW1. The sequence of the PL motif peptide is GSTAPPLPR (GS arises from the BamHI restriction enzyme site).
Lyophilized FBP11 WW1 and the PL motif peptide were dissolved into solution for NMR measurements. The final composition of the solution was 50 mM NaH 2 PO 4 , 50 mM NaCl, 0.02% NaN 3 , 10/100% D 2 O, the PL motif peptide, and FBP11 WW1, pH 5.0. Sample A was 1.5 mM uniformly 15 N-or 13 C/ 15 N-labeled FBP11 WW1 mixed with 5.3 mM natural abundance PL motif peptide. Sample B consisted of the reverse labeling scheme with 4.4 mM 13 C/ 15 N-labeled PL motif peptide and 1.6 mM natural abundance FBP11 WW1.
NMR Measurements-NMR spectra were acquired at 10°C on Varian Unity INOVA 500 and 600 spectrometers equipped with a Narolac z axis gradient probe and a Varian Cold Probe, respectively. All NMR experiments were carried out using the Varian BioPack module on the operation program VNMR, except for 13 C-edited NOESY and 13 C F1-filtered, F3-edited NOESY-HSQC. The pulse program for 13 C-edited NOESY was supplied by Dr. Ogura, which is based on hyperbolic secant 13 C inversion pulses (18) . Assignments of backbone and aliphatic side chains were carried out with Samples A and B using triple resonance spectroscopy data based on the conventional sequential method (19 Structural Analysis-All NMR data were processed with NMRPipe and analyzed with SPARKY3 (21) . The automatic NOE assignment module CANDID, implemented in the program CYANA-2.0, was used for the structure calculation (22) . angle restraints were obtained from solving the Karplus equation based on the results from HNHA with tolerance of Ϯ25° ( 19) . Hydrogen-bonding restraints were obtained from the results of the D 2 O/H 2 O exchange experiment with 15 N-labeled Sample A. The quality of the final structures was assessed using the output file of CYANA-2.0 and PROCHECK-NMR (23) .
Binding Experiment for Mutant FBP11 WW1 and the PL Motif Peptide-A series of mutants of FBP11 WW1 were produced with QuikChange (Stratagene) and were expressed and purified by the same method used for WT FBP11 WW1. The PL motif peptide and related mutant peptides for binding analysis were synthesized with the solid-phase method using Fmoc (N-(9-fluorenyl)methoxycarbonyl)-protected amino acids (Novabiochem). Detailed information regarding peptide synthesis, purification, and surface plasmon resonance (SPR) experiments has been reported previously (24) . We used a BIAcore 2000 (Biacore AB) for SPR experiments with a CM5 sensorchip (Biacore AB), in which the peptides were covalently bound on the sensorchip and FBP11 WW1 and its mutants were injected through flow cells as analytes. SPR equilibrium binding data were used to determine equilibrium constants of ligand peptide binding to FBP11 WW1 by Scatchard plot analysis. Scatchard analysis allows valid calculation of dissociation and association constants in the event that initial non-equilibrium phase kinetic SPR data provide insufficient data points for calculation of rate constants. Details of Scatchard plot analysis are as follows (24) . Raw sensorgrams of flow cell without ligand peptide were subtracted from the corresponding raw sensorgrams of ligand-bound flow cell for each sensorgram before Scatchard plot analysis. RU eq /C values were plotted against RU eq , where RU eq is SPR response in equilibrium and C is the millimolar concentration of an analyte. Plotted data were fit to the equation: RU eq /C ϭ ϪK A ϫ RU eq ϩ A, where A is a constant.
Model Construction of Related WW Domain-Ligand
Complexes-Homology modeling was carried out using the Swiss-MODEL (25) . All models were constructed using the structure of the complex of FBP11 WW1 and the PL motif (Protein Data Bank code 2DYF) as a template.
RESULTS
We adopted a PL motif ligand of yeast Bbc1p to reduce the number of Pro residues as much as possible in determination of the NMR structure, because signal assignment of successive Pro residues is sometimes difficult. Many sequences similar to this Bbc1p PL motif are found in mammalian proteins. The NMR analyses allowed us to unambiguously assign all protons in FBP11 WW1 and the PL motif peptide, except for some side chain protons such as hydroxyl protons of Ser, Thr, and Tyr and amide protons of His, Arg, and Lys. Data from 15 N-edited NOESY and 13 C-edited NOESY with a mixing time of 350 ms were used for structural calculation. The molecular weights of FBP11 WW1 and the PL motif ligand are so small that few cross-peaks were observed when the mixing time was reduced to less than 250 ms. We also confirmed with two-dimensional experiments that no spin diffusion occurred with the 350-ms mixing time. The structure outputs of CYANA-2.0 are shown in Fig. 1 , which are the superimposition of 20 automatically selected output structures out of 100 calculated structures. The structural statistics are listed in Table 1 . We obtained entirely sufficient restraints for torsion angle, hydrogen bonding, and distance, including numerous inter-molecule NOE restraints from purely experimental procedures, so that we see a good convergence of output structures and agreement with the Ramachandran plot despite the quite weak interaction between the two molecules in the complex. Using CYANA-2.0 was also a great advantage in obtaining such a well defined structure. Structural convergence was observed over the range of Trp-12 through Pro-37 of FBP11 WW1, and of Ala-4Ј 3 through Pro-8Ј of the ligand, with backbone root mean square (r.m.s.) deviation values of 0.04 Ϯ 0.02 and 0.03 Ϯ 0.02 Å, respectively.
Overall Structure-The overall structure shows an antiparallel triple-stranded ␤-sheet with a typical WW fold ( Fig. 2A) . FBP11 WW1 is 28 residues long, not including two residues that came from the vector into the construct. The side chains of Trp-12, Tyr-24, and Pro-37 come in contact with each other and form a small hydrophobic core that maintains the architecture of FBP11 WW1.
The PL motif ligand binds FBP11 WW1, intersecting the row of the strands of FBP11 WW1 in a nearly perpendicular manner. Ala-4Ј to Pro-8Ј of the ligand, the converged region, directly contacts the surface of FBP11 WW and forms a PPII helix structure, which is often seen in Pro-rich sequences. Thus, the entire -Pro-Pro-Leu-Pro-sequence of the PL motif contributes to the binding. The orientation of the binding ligand against FBP11 WW1 is the same as that of the phosphorylated C-terminal domain of RNA polymerase II peptide against the Pin1 WW domain (Pin1 WW).
Contact Surface-Two grooves are seen on the surface of FBP11 WW1. The grooves consist of several aromatic residues, 3 The residue names with a prime are those of the PL ligand. Number of nonglycine and nonproline residues 600 and the ligand fits well onto the grooves (Fig. 2B) (Fig. 3) . Structural validity of the mutants of FBP11 WW1 and the PL motif ligand was confirmed with CD analysis (see supplemental Fig. S1 ). Absolute loss or significant decrease of binding was observed with replacement of His-15, Ser-17, Tyr-23, Tyr-25, Ser-32, and Trp-34 of FBP11 WW1 (Fig. 3C) . These residues compose the XP groove, XP2 groove, or Ali-patch. Replacing Trp-34 with Phe or Ala causes area reductions of the XP groove and Ali-patch. The hydroxyl group of Tyr-23 backs the pyrrolidine ring of Pro-5Ј and interacts with side chain of Ala-4Ј, consequently, replacement with Phe in Y23F leads to loss of these interactions. Loss of an aromatic ring at positions 15 or 25 leads to a defect of the XP2 groove. Substitution by Phe and His at position 25 resulted in binding strength comparable with that of WT, suggesting that an aromatic ring is necessary at this position to form the XP2 groove (Fig. 3C ). S17D and P18A show large decreases in binding, whereas S17A does not. S17D shows complete loss of binding, possibly due to the prevention of complex formation by steric exclusion against Leu-7Ј on the ligand, because the side chain of Asp is bulkier than that of Ser. C␦ and H␦ of Pro-18 are in contact with the side chain of Leu-7Ј. The replacement of Pro with Ala results in loss of this Side chains in magenta are in direct contact with the ligand. Wire in pale blue is the backbone of the ligand flanked with its side chains in yellow-green. The side chain of Thr-13 is again shown in orange. B, the surface of FBP11 WW1 is represented with the PL ligand depicted as a yellow wire. The XP groove, XP2 groove, and Ali-patch are circled with blue, navy, and green-yellow ovals, respectively. Surface representation and calculation of electrostatic potential is carried out using MOLMOL (36) . The kT/e range of electrostatic surface shading is from Ϫ1.0 (red) to ϩ1.0 (blue). C, schematic model of the ligand-binding mechanism of FBP11 WW1 to a Pro-rich ligand that forms the PPII helix. The numbering of residues corresponds to the PL motif ligand of our structure. The crosshatched surface on the XP groove is a part of the Ali-patch. Pro-5Ј is recognized in a perpendicular manner by the XP2 groove, whereas the XP groove grasps the Leu-7Ј to Pro-8Ј sequence in parallel with the Trp-34 plane. The side chain of Pro-6Ј comes in contact with an edge of the XP2 groove. The two grooves of FBP11 WW1 primarily recognize four successive residues. D, the binding mechanism of SH3 domains to a Pro-rich ligand forming the PPII helix (37) . In contrast to FBP11 WW1, both XP grooves align in parallel and recognize the respective Xaa-Pro sequences in a parallel manner. In addition, the SH3 domains do not recognize a residue (indicated by green asterisk) lying between two Xaa-Pro sequences in the ligand.
interaction, which explains the decreased binding of P18A. On the other hand, the hydroxyl group of Ser-17 does not interact at all with the PL ligand, so that Ala substitution results in slightly stronger binding by S17A than that of WT.
Systematic substitutions in the PL ligand demonstrated which amino acid positions and properties are vital to optimum binding (Fig. 3D) . P8ЈA shows complete loss of binding. H␥ and H␦ protons of Pro-8Ј directly interact with both the indole ring of Trp-34 and H␤ of Ser-32. H␤ of Ser-32 is also surrounded by H␣ and H␤ protons of Pro-8Ј. These interactions are not possible with Ala substituted for Pro-8Ј, which explains the loss of binding. L7ЈA also showed a large decrease in binding because the side chain of Leu-7Ј is in contact with a large area of FBP11 WW1 and loss of such a large aliphatic residue leads to a significant loss of the van der Waals interaction. Pro-5Ј and Pro-6Ј interact with the XP2 groove, and substitutions by Ala at these residues cause a significant decrease in binding. A4ЈG shows a relatively small but significant decrease in binding, which corresponds to the interaction of H␤ of Ala-4Ј with side chains of His-15 and Tyr-23. Other mutations also resulted in small changes in the K D value of the binding from that of WT.
DISCUSSION
We have solved and described the structure of the FBP11 WW1-PL motif peptide complex by NMR analyses and, using SPR, verified the binding mechanism by studying the effect of amino acid substitutions in FBP11 WW1 and the PL peptide ligand on binding. FBP11 WW1 is an important member of the Group II/III WW domains and the PL motif is one of ligands that interact with these WW domains. FBP11 WW1 shows the typical WW fold formed by triple ␤-strands, with the PL motif ligand intersecting the row of the strands. The ligand is recognized by the XP groove, XP2 groove, and Ali-patch on the surface of FBP11 WW1. His-15, Ser-17, Pro-18, Tyr-23, Tyr-25, Ser-32, and Trp-34 form the contact surface that interacts with the ligand. Replacement of each of these residues in FBP11 WW1 resulted in significant decreases in binding. Mutations of Pro-5Ј through Pro-8Ј on the ligand resulted in a severe decrease in binding. The results from the structural and binding analyses are therefore completely consistent.
The XP and XP2 grooves lie approximately perpendicular to each other on the surface of FBP11 WW1. Pro residues are recognized in different manners in the XP compared with the XP2 groove (Fig. 2C) . In contrast, the two XP grooves on an SH3 domain align themselves nearly in parallel and recognize the Pro-rich ligand in a manner similar to each other (Fig. 2D) . Thus, the ligand-recognition mechanism of FBP11 WW1 is unlike that of the SH3 domains.
Group I and IV WW domains bind to ligands in exactly the opposite orientation (7, 8, 26) . Pin1 WW, a Group IV WW domain, binds a -Ser(P)/Thr(P)-Pro-motif peptide in the "plus" orientation, whereas Dys WW, a Group I WW domain, binds a -Pro-Pro-Xaa-Tyr-sequence in the "minus" orientation (Fig. 4, A and C) . The PL motif ligand adopts the PPII helix conformation that has a pseudo-2-fold symmetry. It has therefore been predicted that both orientations of ligand binding are possible in the case of Group II/III WW domains (11) . However, the FBP11 WW1-PL motif complex were found preferably to adopt the plus orientation (Fig. 4B) , which is likely to be defined by the interaction between Leu-7Ј and the Ali-patch.
We have recently reported the structure of ligand-free FBP11 WW1 (16) . Our findings indicate that the mean structures of the free and ligand-complexed forms of FBP11 WW1 are quite similar to each other, with a backbone r.m.s. value of 0.75 Å over Trp-12 to Pro-37 between the two forms (Fig. 4, D and E) . In addition, the complexed form of FBP11 WW1 determined by us is more similar to the complexed forms of WW domain crystal structures such as those of dystrophin (Dys WW) and Pin1 (Pin1 WW), with backbone r.m.s. values of 0.75 and 0.96 Å, than to the free forms of Dys WW and Pin1 WW, respectively (Fig. 4E) . Thus, the complexed forms of WW domains from all groups are similar to each other.
Pires et al. (15) have recently reported the structures of the free and ligand-complexed forms of FBP11 WW1. Their and our structures of the complexed form of FBP11 WW1 differ with a backbone r.m.s. value of 1.13 Å over Trp-12 to Pro-37 (8) . The peptide ligand (pink) and some residues on the WW domain (gray) are shown in bond representation. The ligand contains a -Pro-Pro-Xaa-Tyr-sequence, the Group I ligand motif. The N-terminal Pro residue of the ligand binds to the XP groove, whereas the C-terminal Tyr binds to the Tyr-groove (minus orientation). B, the XP groove of FBP11 WW1 (Group II/III) binds to the C-terminal portion of the PL motif ligand (plus orientation). The ligand is colored orange. C, orientation of the ligand against Pin1 WW (Group IV) is also the plus orientation (26) . The ligand, containing a Ser(P)/Thr(P)-Pro motif, is colored in blue. The ligand is phosphorylated on its Ser residue, which is accommodated by the p-patch on the Loop I region of Pin1 WW. The following Pro residue of the ligand is recognized by the XP groove. D, superimposition of WW domains. Pink, orange, and blue bonds represent the complex forms of WW domains of dystrophin (Group I), and FBP11 (WW1) (Group II/III), and Pin1 (Group IV), respectively. The red bond represents FBP11 WW1 in the ligand-free form (16) . E, backbone r.m.s. values (Å) between the WW domains in the free and complex forms. r.m.s. values against the FBP11 WW1 free and complex forms are calculated using the mean structure of these WW domains. (Fig. 5) . Their and our whole complex structures differ with a backbone r.m.s. value of 1.23 Å. In addition, the relative arrangement of FBP11 WW1 and its ligand in our complexed structure significantly differs from the structure they reported (Fig. 5) . Pires et al. (15) also reported that the structure of FBP11 WW1 drastically changes upon the binding of its ligand. They reported that the conformational change of the Loop I region is notably large. In contrast, we did not observe a large change in the structure of FBP11 WW1 upon ligand binding (see supplemental Fig. S2 ), which is supported by relatively small chemical shift changes of the residues in the Loop I region upon addition of the PL ligand into the NMR solution of FBP11 WW1 (see supplemental Figs. S3 and S4) .
The difference in the relative arrangement of the complex and the backbone of FBP11 WW1 leads to that in the detailed recognition manner of the PL ligand by FBP11 WW1. In contrast to Pires et al. (15) we did not observe the interaction of Thr-13 of FBP11 WW1 with the ligand and that of Trp-34 with the 9th residue in the ligand. Instead, we did observe the interaction by Ala-4Ј of the ligand with FBP11 WW1. The SPR data of FBP11 WW1 binding to mutants A4ЈG and R9ЈA of the ligand supports our observation. In addition, the direction of the side chain of Leu-7Ј of the ligand is different. As a result, the binding sequence in the ligand proposed by Pires et al. (15) is -Pro-Pro-Leu-Pro-Xaa-, whereas we propose that the -XaaPro-Pro-Leu-Pro-sequence is important, which might reflect that FBP11 WW1 has multiple modes of binding to the PL motif. The structural discrepancy between our structure and that of Pires et al. (15) may be due to different experimental conditions such as the ligand sequence, pulse programs, isotope-labeling strategy of the ligand, and the software used for the structure calculations. We have other supporting data for the validity of our structure than the results of the mutational analysis. The first is the results of the titration experiment mentioned above. The second is the number of NOE constraints. We obtained more than double the 48 medium range, 150 long range, and 40 inter-molecule NOE constraints that they reported.
FBP28 and FCA are proteins having WW domains similar to FBP11 WW1. We built models of these WW domains complexed to ligand using our structure of the FBP11 WW1-PL motif complex as a template. FBP28 is a key protein in neurological diseases such as Huntington disease (3, 4, 27) . It is expected that the second WW domain of FBP28 (FBP28 WW2) binds to the polyproline region of huntingtin as does FBP11 WW1 (2, 5, 11) . In A. thaliana, binding of FCA WW to FY, an RNA 3Ј End-Processing Factor, is essential to regulating the expression of FLC, a floral repressor, and FCA itself to control flowering time (6) . Models of complexes of FCA WW-PL ligand and FBP28 WW2-polyproline (PP) ligand were built by the Swiss-MODEL homology modeling tool (Fig. 6) . In both cases, ligands fit efficiently onto the WW domains, and the modeled configurations of the WW domains and ligands were similar to the FBP11 WW1-PL motif complex. Both models show the ligand to be accommodated by a similar configuration of the XP groove, XP2 groove, and Ali-patch. In the case of FCA WW, the residues that compose the XP groove, XP2 groove, and Alipatch are completely identical to those of FBP11 WW1 (Fig. 6,  A and B) . FBP28 WW2 is different from FBP11 WW1 and FCA WW in the Ali-patch region, having Thr-17 and Ala-18 instead of Ser-17 and Pro-18, resulting in weaker binding to the PL motif (5, 17) . Instead of Ser, FBP28 WW2 has Thr-17, whose C␥ may hinder binding of Leu-7Ј in PL ligands to FBP28 WW2, but Thr-17 does not interfere at all with Pro-7Ј in PP ligands binding to FBP28 WW2 as shown in Fig. 6C . With both FCA WW and FBP28 WW2, the mechanism of binding Pro-rich ligands should be quite similar to that of FBP11 WW1. FBP11 WW1 and other Group II/III WW domains bind to various Pro-rich motifs (10 -12) . Thus, the Ali-patch of the Group II/III WW domain is probably a site that accommodates various kinds of residues, probably aliphatic side chains, in Pro-rich motifs including the PL and PP motifs, and to some extent defines the predilection of ligands, leading to the loose specificity of the Group II/III WW domains, which was formerly demonstrated by exhaustive binding experiments (10 -12) .
FY, huntingtin, MeCP2, and N-WASP contain PP or PL motifs that are recognized in vivo by FBP11 WW1 and related WW domains (2, 4, 6, 12, 28) . In Huntington disease patients, spliceosome proteins that contain the Group II/III WW domains, including FBP11 and FBP28, are involved in formation of huntintin aggregates (3, 27) . These aggregates are associated with neurodegeneration, and inhibit cellular activities of Group II/III WW domain-containing proteins, which may enhance the progression of Huntington disease. FBP11 is a modulator protein that has the WW and FF domains, and acts as a splicing factor and negative regulator for microspike formation of neurons (1, 28) . In addition, Prp40, the yeast ortholog of FBP11, binds the branch-point bridging protein, U5 small nuclear ribonucleoprotein-associated protein (29, 30) , U1 small nuclear ribonucleoprotein, and C-terminal domain of RNA polymerase II of RNA polymerase II (31, 32) . RNA polymerase II is the main coordinator for pre-mRNA processing events, and CA150, another homologue of FBP11, assembles the splicing complex (33) . Recent study has shown that MeCP2 regulates excitatory neurotransmission by repressing transcription (34) . Taken together, these results suggest that the WW domains of FBP11 and related proteins are likely to recruit MeCP2 to the splicing complex, leading to the regulation of neurotransmission. In fact, the loss of the C-terminal PL motif of MeCP2 leads to the loss of binding to FBP11 and the other Group II/III WW domains, which causes the progression of Rett syndrome, in which patients show stereotypical hand movement, loss of acquired speech and motor skills, seizures, and mental retardation (4) . Interactions by the WW domains of FBP11 and related proteins with Pro-rich motifs therefore have key roles in severe neurogenetic disorders.
In FCA, FBP28, and FBP11, the Group II/III WW domain recognizes 5-residue-long Pro-rich sequences, whereas SH3 domains and profilin require longer recognition sequences. The binding mechanism of the Group II/III WW domain is significantly different from that of the SH3 domain, as the XP2 groove recognizes the Pro residues in a perpendicular orientation, which enables the Group II/III WW domain to identify such short sequences. Thus, only the Group II/III WW domains can bind short Pro-rich sequences.
Because the consensus sequence -Xaa-Pro-Pro-Leu-Proproposed by us is different from -Pro-Pro-Leu-Pro-Xaa-proposed by Pires et al. (15) , drug designers may have to consider ligand designs that encompass both of these possibilities in designing drugs for neuronal diseases. Whereas Pires et al. (15) reported drastic changes in the structure of FBP11 WW1 upon ligand binding, we observed a small structural fluctuation of FBP11 WW1 upon ligand binding, resulting in Thr-13 not emerging onto the surface of the XP2 groove, which implies the structural robustness of the XP2 groove. As a result, our results suggest that FBP11 WW1-mimic drugs would not have to have a flexible structure, or may be replaced by small organic chemicals. Thus, the differences between the binding mechanisms of FBP11 WW1 to the PL motif we report here and those reported by Pires et al. (15) raise the important issue of which structure is most accurate upon which to base drug design strategies.
There are numerous proteins that contain Pro-rich sequences, as the Pro-rich sequence is the most frequently occurring protein motif in the eukaryote genome (35) . Group II/III WW domains including FBP11 WW1 recognize Pro-rich FIGURE 6 . Model structures of complexed Group II/III WW domains. A, alignment of the four WW domains that are highly similar to FBP11 WW1. Red characters show the residues that compose the XP groove, XP2 groove, or Ali-patch. Asterisks and dots show completely identical and similar residues among these four proteins, respectively. We use the residue numbering system that we previously defined to facilitate comparison to other WW domains (11, 24) . Based on this system, we number the second Trp the 34th residue, which is 168th in the whole FBP11/HYPA sequence. The arrows show the positions of the ␤-strands. The intervals between the ␤-strands are referred to as Loops I and II. B, the FCA WW domain complexed with the PL motif, which is colored orange. C, the FBP28 WW2 domain complexed with polyproline, the PP motif, which is colored orange.
sequences in a great variety of proteins, implying potential roles in many diverse biological events (10 -12) .
